ArticleBMC pregnancy and childbirth2025
Characteristics of neonatal necrotizing enterocolitis in relation to the presence or absence of patent ductus arteriosus.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThe presence of a patent ductus arteriosus (PDA) increases the morbidity and mortality rates in neonates with necrotizing enterocolitis (NEC), attributable to the "diastolic steal" phenomenon. Consequently, it is vital to assess the characteristics of NEC in relation to the presence or absence of PDA.
methodsA retrospective case-control study was conducted from 2015 to 2022, encompassing 135 neonates who were categorized into mild and severe NEC groups, with each group further divided into NO-PDA and PDA subgroups. Demographic characteristics of both mothers and neonates, as well as neonatal respiratory mechanics, hematologic parameters, and echocardiographic data were meticulously collected. Logistic regression analyses were conducted, and the results were statistically processed using the R programming language.
resultsIn the mild NEC group, 46.9% (38/81) of neonates had the presence of PDA, compared to 53.7% (29/54) in the severe NEC group. Additionally, a lower left ventricular systolic function and a higher incidence of moderate to severe tricuspid regurgitation were observed in the PDA subgroup of the severe NEC group (P < 0.05). The occurrence of increased blood urea nitrogen, positive blood culture results in cases of sepsis, heart failure, and intraventricular hemorrhage was 1.27, 1.60, 1.91, and 3.86 times higher, respectively, in the PDA subgroup than in the NO-PDA subgroup. Within the PDA subgroup, for every one gram per liter decrease in fibrinogen, the incidence risk of NEC increased by 65%, and for each one mmol/L decrease in calcium levels, the incidence risk of NEC increased by 89% after adjustment.
conclusionsHsPDA in neonates not only affects the severity and progression of NEC but also exerts an impact on multi-system functions. This includes exacerbating respiratory issues (due to high pulmonary blood flow and increased need for ventilatory support), increasing the load on the left ventricular blood flow, promoting hypercoagulability, disrupting calcium metabolism, and raising the risk of sepsis and IVH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.